title: Screening and management of adverse endocrine outcomes in adult survivors of childhood and adolescent cancer.
abstract: 5 year survival for childhood and adolescent cancer in developed countries is now in excess of 80% and the number of survivors of cancer continues to increase worldwide. After completion of therapy, many of these survivors will face a lifelong risk of endocrine late effects. We summarise the available evidence related to the prevalence and risk factors for endocrine late effects among adult survivors of childhood and adolescent cancer. Present screening, surveillance, and treatment recommendations differ by country and region, so we also highlight the continued effort to harmonise the international guidelines for this population.
authors: Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
authors: Emily S
authors: ES
authors: Tonorezos
authors: Departments of Oncology, Epidemiology and Cancer Control, and Psychology, St Jude Children's Research Hospital, Memphis, TN, USA.
authors: Melissa M
authors: MM
authors: Hudson
authors: Department of hematology and Oncology, Royal Hospital for Sick Children, Edinburgh, Scotland.
authors: Angela B
authors: AB
authors: Edgar
authors: Department of Paediatric Oncology, Emma Children's Hospital and Academic Medical Centre, Amsterdam, Netherlands.
authors: Leontien C
authors: LC
authors: Kremer
authors: Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
authors: Charles A
authors: CA
authors: Sklar
authors: Department of hematology and Oncology, Royal Hospital for Sick Children, Edinburgh, Scotland.
authors: W Hamish B
authors: WH
authors: Wallace
authors: Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Electronic address: oeffingk@mskcc.org.
authors: Kevin C
authors: KC
authors: Oeffinger
mesh_terms: D000293:Adolescent; D000328:Adult; D000970:Antineoplastic Agents / Q000009:adverse effects; D019468:Disease Management; D004700:Endocrine System Diseases / Q000175:diagnosis* / Q000209:etiology / Q000628:therapy*; D006801:Humans; D009369:Neoplasms / Q000628:therapy*; D011878:Radiotherapy / Q000009:adverse effects; D012307:Risk Factors; D017741:Survivors; D055815:Young Adult
chemical_list: D000970:Antineoplastic Agents